Multi center clinical and animal model study on the Expression of the miR-155-5p/DUSP14/MAPK Pathway and the Mechanism of Inflammatory Injury in Children with Temporal Lobe Epilepsy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500100391

Enrollment

Unknown

Registered

2025-04-08

Start date

2025-05-01

Completion date

Unknown

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

epilepsy group:NA

Eligibility

Sex/Gender

All

Age

4 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Age 4-14 years. 2. Diagnosed with epilepsy according to the 2017 ILAE guidelines and 2015 China Anti-Epilepsy Association (CAAE) diagnostic and treatment guidelines, based on clinical manifestations, electroencephalogram (EEG) findings, and neuroimaging results. 3. No history of:Other neurological disorders.Head trauma with loss of consciousness.Abuse of psychostimulants, opioids, alcohol, or nicotine dependence (for both participants and their parents). 4. Written informed consent obtained from both the child and their legal guardian.

Exclusion criteria

Exclusion criteria: 1. Patients with congenital diseases or chromosomal abnormalities. 2. Children currently participating in other clinical trials. 3. Children with visual or hearing impairments. 4. Patients with comorbid neurodevelopmental disorders (e.g., obsessive-compulsive disorder, attention deficit hyperactivity disorder, selective mutism). 5. Poor compliance (unable to complete the trial) or unwilling to participate.

Design outcomes

Primary

Measure	Time frame
miR-155-5p;	—

Countries

China

Contacts

Public ContactFang Qiong

Fujian Provincial Hospital Affiliated to Fuzhou University

tiantian3618@163.com+86 135 5945 2648

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026